Fly News Breaks for January 3, 2020
Jan 3, 2020 | 08:45 EDT
RBC Capital analyst Brian Abrahams lowered his price target on Incyte to $80 and kept his Sector Perfor rating after its GRAVITAS-301 study of itacitinib+corticosteroids failed to meet the primary and secondary end points in patients with GVHD. The analyst notes that the results were a "disappointment" given itacitinib's opportunity in the broader early-line setting and the company's global rights to the drug, but he also anticipates the impact to be "relatively modest" as investors were likely "reasonably conservative" given the "limited prior data and complex pathophysiology" for the drug.
News For INCY From the Last 2 Days
Feb 16, 2020 | 15:57 EST
Specialty Pharma Analyst Chen, Biotech Analysts Young & Merle, along with Key Opinion Leaders Dr. Goldberg, Skin Laser & Surgery Specialists of NY & NJ and Dr. Weinberg, Forest Hills Dermatology Group, discuss the competitive landscape in atopic dermatitis at a Group Luncheon Meeting being held at Cantor's New York offices on February 24 at 12 pm.